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E-mail: hamblin@helix.mgh.harvard.eduSepsis is characterized as an uncontrolled host response to
infection, and it represents a serious health challenge, causing
excess mortality and morbidity worldwide. The discovery of
sepsis-related epigenetic and molecular mechanisms could
result in improved diagnostic and therapeutic approaches,
leading to a reduced overall risk for affected patients. Accumu-
lating data show that microRNAs, non-coding RNAs, and exo-
somes could all be considered as novel diagnostic markers for
sepsis patients. These biomarkers have been demonstrated to
be involved in regulation of sepsis pathophysiology. However,
epigenetic modifications have not yet been widely reported in
actual clinical settings, and further investigation is required
to determine their importance in intensive care patients.
Further studies should be carried out to explore tissue-specific
or organ-specific epigenetic RNA-based biomarkers and their
therapeutic potential in sepsis patients.
Sepsis is a potentially life-threatening condition, which occurs
because of an uncontrolled response of the body to an infection.1,2
Sepsis can result in different types of organ dysfunction and the
occurrence of secondary infections. The condition called “septic
shock” can cause up to 40% mortality in hospitalized patients.2,3
More than 80% of the primary genetic elements have been changed
in the critically ill based on genome-wide analysis of gene expression.4
In 1992, the concepts of “systemic inflammatory response syndrome”
(SIRS), sepsis, severe sepsis, and septic shock were originally defined
by the American College of Chest Physicians and the Society of Crit-
ical Care Medicine (SCCM). In SIRS, two or more of the following
symptoms are required: temperature >38C or <36C, heart rate
>90 beats/min, respiratory rate >20 breaths/min or arterial CO2 ten-
sion <32 mmHg or a need for mechanical ventilation, or white blood
cell count >12,000/mm3 or <4,000/mm3. SIRS arising from an infec-
tion is defined as “sepsis,” whereas “severe sepsis” includes evidence
of acute organ dysfunction (e.g., hypotension, lactic acidosis, throm-
bocytopenia). Sepsis with persistent hypotension after fluid resuscita-
tion is called “septic shock.”5 After much research into the concept of
sepsis, and analysis of the clinical evolution of the disease, it has beenMolecular Therap
This is an open access article under the CC BY-NCconcluded that SIRS, sepsis, severe sepsis, and septic shock occur
along a continuum of disease severity, rather than as discrete clinical
entities. Finally, in 2016, new consensus definitions of sepsis were
published by the European Society of Intensive Care Medicine and
the SCCM. The revised definitions included the following: the terms
SIRS and severe sepsis were omitted; sepsis is now defined as life-
threatening organ dysfunction caused by a dysregulated host response
to infection; and septic shock is defined as a subset of sepsis in which
underlying circulatory, metabolic, or cellular abnormalities are suffi-
ciently severe to substantially increase mortality rates.5
Non-coding RNAs are responsible for the regulation of many cell
signaling pathways. These molecules include long non-coding
RNAs (lncRNAs), circular RNAs (circRNAs), and microRNAs (miR-
NAs), which are involved in several biological processes such as
apoptosis, mitochondrial dysfunction, and innate immunity.6–10
lncRNAs are transcripts containing more than 200 nt, whose mecha-
nisms of formation and function have been recently investigated.11,12
According to some experimental studies, the differential expression of
some lncRNAs has been found in cardiomyocytes, monocytes, and
human tubular epithelial cells, when subjected to the addition of
plasma obtained from septic patients, or, alternatively, the addition
of pure lipopolysaccharide (LPS).13–15 However, the function of these
lncRNAs in sepsis still remains unclear. Human umbilical vein endo-
thelial cells were screened for lncRNAs, and the results showed 28- to
70-fold increases in the expression of these non-coding RNAs after
LPS exposure.16 These changes could be involved in the modulation
of inflammatory responses. For example, the lncRNA called lnc-IL7Ry: Nucleic Acids Vol. 21 September 2020 ª 2020 The Author(s). 51
-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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receptor a subunit to reduce the proinflammatory responses induced
by LPS.17 Additionally, the lncRNA HOTAIR has been shown to
modulate tumor necrosis factor (TNF)-a synthesis in cardiomyocytes
in a murine sepsis model via the nuclear factor kB (NF-kB)
pathway.14
circRNAs are known as a class of lncRNAs,18 which are stabilized by
their circular structure, and have been proposed to function as bio-
markers for various conditions. Despite the limited availability of
data concerning any proven association between these molecules
and the condition of sepsis, in vitro knockdown of the circRNA
known as RasGEF1B suggested a complicated relationship between
several cellular pathways occurring in sepsis.19
All cells (both diseased and healthy) are able to synthesize 21- to 25-nt-
long RNA molecules called miRNAs. These miRNAs bind to comple-
mentary sequences in the untranslated 30 end of their target mRNAs,
and they are able to post-transcriptionally regulate the expression of
numerous genes.20 Somewhat confusingly, they can have protective
or detrimental effects in different immune-related disorders and can
affect the levels of the pro-inflammatory cytokines TNF-a and IL-1b
through signaling pathways involving p38 mitogen-activated protein
kinase (MAPK) and MAPK phosphatase 1 (MKP-1).6–9,21–23 The re-
sults of case-control studies showed that there was differential expres-
sion of some miRNAs in septic patients compared to control patients.
These authors suggested that miRNAs could be biomarkers for diag-
nosis or prognostic stratification, and they could even possibly be ther-
apeutic targets in sepsis treatment.7,23–30
A complete understanding of the exact molecular mechanisms
involved in sepsis requires further research.31 Researchers have sug-
gested that the pathophysiology of sepsis is reportedly associated
with the dysregulation of oxidative stress and excessive inflammatory
responses.32 Recent studies have detected extracellular vesicles (EVs)
in the circulation of sepsis patients, and they have suggested that these
EVs could originate from various cells affected by the pathophysi-
ology of sepsis.33–35 Exosomes are a specific kind of EVs derived
from platelets (as well as other cell types), which can trigger the syn-
thesis of superoxide and the induction of apoptosis in vascular cells in
sepsis patients through redox and inflammatory mechanisms.36,37
In one study, a correlation between exosome abundance and cardiac
dysfunction was observed. Cardiac dysfunction was proposed to be
due to myocardial depression caused by exosomes in the isolated
heart preparation and in papillary muscle cells, probably due to
myocardial nitric oxide production.38
Exosomes are reported to be active in cell-to-cell communication,
both in normal tissues and in diseased conditions such as cancer,
due to their contents of functional messenger RNAs (mRNAs) and
also miRNAs.39–41 Although miRNAs have been reported in plasma
from septic patients,42,43 only limited data are available on the nucleic
acid contents of exosomes during sepsis.30,44,4552 Molecular Therapy: Nucleic Acids Vol. 21 September 2020Based on clinical and experimental studies, we herein summarize the
current knowledge about the role of miRNAs, lncRNAs, and exo-
somes in the pathophysiology of sepsis.
lncRNA Biogenesis
The family of lncRNAs characterized as 200-nt non-protein-coding
transcripts,46 contains more than 60,000 individually cataloged mem-
bers based on the database LNCipedia for annotation of human
lncRNA transcript structures and sequences.47 Poorly conserved
lncRNAs might be compensated due to the presence of strong struc-
tural conservation.48 The conserved genomic areas of DNA can tran-
scribe lncRNAs (Figure 1),49 and lncRNAs can also be produced by
back-splicing of exons from circRNAs.50,51 The lncRNAs possess
multiple functions and activities, such as regulation of gene expres-
sion, rearrangement of chromatin, modification of histones, and
alternative splicing of genes, suggesting their possible role in the path-
ogenesis of different diseases and conditions.52,53
circRNAs comprise a large class of non-coding RNAs that are primar-
ily derived from protein-coding gene exons, but they are not pro-
duced by the normal RNA splicing model.54 The main features of
circRNAs are their covalent loop structures due to their 30 and 50
ends being joined together by intron-exon circularization.55 Despite
initial reports that circRNAs had only a low abundance, further
research showed they were indeed more widespread and had a sub-
stantial presence in various transcriptomes.50,51,55
According to Jeck et al.,51 circRNAs can be produced by several mech-
anisms, including exon-intron pairing-driven and lariat-driven circu-
larization, as shown in Figure 2. As shown in Figure 2C, the introns
between the exons are removed after generating a circular structure
to form an exon-only circRNA named EIciRNA, or else they can be
retained to produce an intron-retaining circRNA.51,56 The circulari-
zation of two flanking intronic sequences can also generate circRNAs
(Figure 2).57,58 Many different circRNAs have been shown to be
specific for different organs or tissues, and some of them have been
associated with diseases, suggesting that circRNAs are not merely by-
products caused by splicing or mis-splicing errors.59,60
lncRNAs and Sepsis
It has been previously suggested that dysregulation of lncRNAs is
associated with different diseases, and many lncRNAs have been de-
tected to play significant roles in developmental and biological pro-
cesses.12 However, there have only been a limited number of studies
aiming to assess any correlation between sepsis and lncRNAs (Table
1). Until now, numerous reports have found that the expression of
lncRNAs is altered in human monocytes, cardiomyocytes, and
tubular epithelial cells during the sepsis process or after exposure to
LPS.13–15 Moreover, it was recently shown in human umbilical vein
endothelial cells that several lncRNAs were downregulated (with a
maximum downregulation of about 28-fold), whereas other lncRNAs
were upregulated (with a maximum upregulation of about 70-fold).16
Additionally, Cui et al.17 reported that the lncRNA lnc-IL7R (which
overlaps with the 30 UTR of the a subunit gene of IL-7 receptor)
Figure 1. Long Non-coding RNA (lncRNAs) Biogenesis
(A) Sense: the lncRNA transcript overlaps with exons of the other transcript in the same strand. (B) Antisense: the lncRNA transcript overlaps with exons of the other transcript
in the opposite strand. (C) Intronic: the lncRNA is entirely derived from the intron of a different transcript. (D) Intergenic: the lncRNA sequence is located between the two
genes coding for proteins. (E) Bidirectional or divergent: the lncRNA is located in the opposite strand from a protein coding gene; therefore, they are co-regulated. (F)
Enhancer: the lncRNA, also known as eRNA, is transcribed from the enhancer region.
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signaling in LPS-treated cells. However, the role of lncRNAs has not
been sufficiently explored in sepsis, and further studies are needed to
discover how lncRNAs affect sepsis, and to unravel the precise molec-
ular mechanisms.
Several circRNAs have been recently observed to function as “miRNA
sponges” that can remove specific miRNAs, thereby modulating gene
expression.50,59,61 In sepsis, many miRNAs are differentially ex-
pressed, suggesting that some corresponding circRNAs may also be
implicated. It has been recently found that mcircRasGEF1B, as an
LPS-inducible circRNA, could modulate the stability of mature inter-
cellular adhesion molecule (ICAM)-1 mRNAs, and might be able to
protect cells against microbial infection.19 Improved experimental
characterization and identification of circRNAs, as well as some
related molecules, including miRNAs, are needed to obtain new in-
sights into sepsis pathogenesis and to identify possible novel
biomarkers.
miRNA Biogenesis
miRNAs have been shown to be endogenous non-coding RNA mol-
ecules with lengths of 19–22 nt,62 whose biogenesis has been eluci-
dated in previous studies.63,64 Briefly, RNA polymerase II transcribes
the DNA to produce a primary miRNA known as pri-miRNA having
500–3,000 nt65 (Figure 3). Subsequently, the pri-miRNA is cleavedinto a premature miRNA known as pre-miRNA having 70–80 nt.
This cleavage is caused by the microprocessor complex consisting
of the DiGeorge syndrome critical region 8 (DGCR) protein and
RNase III Drosha enzyme.66 In the next step, the pre-miRNA moves
into the cytoplasm using the exportin-5-mediated nuclear export sys-
tem, which processes the approximately 22-nt miRNA duplex by the
interaction of the co-factor double-stranded transactivation-respon-
sive RNA-binding protein with RNase III endonuclease Dicer pro-
tein.67 Afterward, the integration of miRNA duplex occurs with the
RNA-induced silencing complex (RISC) following binding to glycine
tryptophan repeat-containing protein and argonaute protein, which
bind to full or partial sequences in the 30 or 50 UTR of the target
mRNA.20,68 The miRNAs are involved in a comprehensive gene regu-
lation network in the pathophysiology of numerous disease
conditions.69,70
miRNAs and Sepsis
miRNAs play significant roles in the regulation of adaptive and innate
immune responses during the pathogenesis of diseases such as sepsis
(Table 2).71 These biomarkers are able to regulate the development of
regulatory T cells and T helper cells, which are essential to optimizing
the host responses to infectious disease.72,73 During sepsis, the im-
mune system of the host appears to be both immunosuppressed,
while at the same time being in an accentuated pro-inflammatory
state.74,75 In this pro-inflammatory state, numerous cytokines areMolecular Therapy: Nucleic Acids Vol. 21 September 2020 53
Figure 2. Circular RNA (circRNA) Biogenesis Pathways
(A) Lariat-driven circularization. (B) Intron pairing-driven circularization. (C) Circular intronic RNAs. (D) RNA-binding protein (RBP)-driven circularization.
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of TNF-a at both translational and transcriptional levels. For
instance, one investigation carried out by Dan et al.76 found that
miR-181 upregulation enhanced the degradation of TNF-a mRNA.
Likewise, another study showed that miR-125b was considerably
reduced in correlation with higher expression of TNF-a in neonatal
monocytes after LPS stimulation.77 Furthermore, miRNAs can also
target the TNF pathway and mediate the inflammatory response.
miR-511 was suggested to act as a regulator of TNF receptor 1 protein
and to affect the sensitivity of cells to TNF, thus possibly protecting
against TNF-dependent endotoxic shock syndrome.78 Moreover, it
has been also shown that other inflammatory cytokines, such as IL-
6, are considerably increased in patients with sepsis.79 In fact, Zhou
et al.80 showed that miR-146a downregulation was correlated with
increased concentrations of IL-6 in sepsis patients.
Numerous investigations have reported that miRNAs are capable of
regulating inflammatory responses via targeting the Toll-like receptor
(TLR) signaling pathway (Figure 4). TLR-induced signaling primarily
activates NF-kB, a key transcription factor modulating the expression
of pro-inflammatory and immunoregulatory factors.81–83 Some miR-
NAs, such as miR-155, miR-125, and miR-146a, were found to play
essential roles in the negative modulation of the TLR/NF-kB-induced
inflammatory cascade and in innate immunity.84–86 The expression of
miR-155 and numerous other miRNAs is NF-kB-dependent.87 For54 Molecular Therapy: Nucleic Acids Vol. 21 September 2020instance, it was found that using LPS to stimulate monocytic THP-
1 cells induced expression of both miR-146a and miR-146b.88
miR-146a directly regulates the expression of TNF receptor-associ-
ated factor 6 (TRAF6) and IL-1 receptor-associated kinase 1
(IRAK1), which are crucial adaptor molecules in the TLR signaling
pathway.81,82,89 In addition, miR-146a plays an important role in
the endotoxin tolerance of monocytic cells in vitro,90,91 and this toler-
ance could be reversed by suppressing miR-146a.91 It has recently
been reported that the NF-kB/DICER signaling pathway inhibited
TNF-a expression by producing mature forms of miR-130a and
miR-125b, thus regulating TNF-a mRNA.92 It is known that the
TLR-induced signaling pathway is critical in sepsis.93
As the sepsis condition progresses, the immune response is
reprogrammed into a more immunosuppressed state.75,94 This
immunosuppression is partly induced by miRNAs, which mediate
the polarization of immune cells and alter cellular immunity95–97
(Figure 3). miR-181b and miR-21 were upregulated in myeloid-
derived suppressor cells isolated from septic mice. This expression
prevents the differentiation of precursors into dendritic cells and
macrophages via affecting the transcription factors CCAAT/
enhancer-binding protein b (C/EBPb) and signal transducer and acti-
vator of transcription 3 (Stat3).96,98 Moreover, a temporal modulation
was found in myeloid cells, with miR-155 inversely correlated with
LPS-stimulated levels of brain and muscle ARNT-like 1
Table 1. Selected lncRNAs Involved in Sepsis
lncRNAs Expression in Sepsis Target Gene Effect(s) Model No. of Samples Ref.
MALAT1 up miR-125b
MALAT1 interacts with p38 MAPK/NF-kB and
miR-125b, thereby aggravating cardiac
inflammation and dysfunction in sepsis
mice – 216
NEAT1 up miR-204
the upregulation of NEAT1 was related to the
severity of acute kidney injury (AKI) in sepsis
patients
humans in vitro 55 217
NEAT1 up
circulating lncRNANEAT1 was related to severity,
increased risk, and unfavorable prognosis in sepsis
patients
humans 152 218
NEAT1 up
NEAT1 induced brain injury in septic mice via
positively regulating NF-kB
Mice – 219
NEAT1 up – – humans 59 220
lnc-ANRIL up – – humans 26 221
lnc-ANRIL/miR-125a axis up
lnc-ANRIL/miR-125a axis could serve as a
biomarker for prognosis, severity, and
inflammation in sepsis patients
humans 26 221
HOTAIR up
HOTAIR upregulation leads to HK-2 cell
apoptosis in kidney injury via the miR-22/HMGB1
pathway
rats in vitro – 222
HOTAIR –
HOTAIR overexpression can reduce AKI in septic
rats by suppressing the apoptosis of kidney tissues
via downregulating the miR-34a/Bcl-2 signaling
pathway
Rats – 223
lncRNA H19 down – humans in vitro 69 224
lncRNA ITSN1-2 up
high expression of ITSN1-2 is associated with
disease severity and inflammation in sepsis
patients.
Humans 309 225
HULC up –
upregulation of lncRNA HULC is required for the
pro-inflammatory response during LPS induced
sepsis.
mice in vitro – 226
UCA1
upregulation of UCA1 is needed for the response
of pro-inflammatory immune cells during LPS-
induced sepsis
TUG1 down
decreased TUG1 expression may induce sepsis-
related AKI by modulating the NF-kB pathway
and regulating the miR-142-3p/SIRT1 axis
humans in vitro 28 227
TapSAKI up
TapSAKI promoted the inflammatory response
and HK-2 cell apoptosis through the miR-22/
PTEN/TLR4/NF-kB pathway
rats in vitro – 228
HOTAIR up -
in vivo studies showed that silencing of HOTAIR
could improve cardiac function of septic mice and
significantly reduce TNF-a production
Mice 14
MALAT1 up –
IL-6 induced upregulation of MALAT1 in LPS-
treated cardiomyocytes, and MALAT1 could
promote the expression of TNF-a at least partly by
SAA3 in response to LPS treatment in
cardiomyocytes
mice in vitro – 229
MALAT1 and EZH2 up –
upregulation of MALAT1 and EZH2 were found
in the hearts of rats with sepsis
rats in vitro – 230
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Review(BMAL1).99 Additionally, it has also been demonstrated by other in-
vestigators that different miRNAs, including miR-29a, miR-23b, and
mi-R210, inhibit IL-6 and NF-kB expression during sepsis by
affecting various immune cells.65,100,101 These studies have suggested
a role for miRNA involvement in sepsis pathophysiology.Non-coding RNAs as Therapeutic Targets
Experimental investigations have suggested that the measurement of
non-coding RNAs and the use of miRNA modulators could be of
some benefit in the fight against sepsis. However, in order to translate
these biomarkers into real clinical applications, considerableMolecular Therapy: Nucleic Acids Vol. 21 September 2020 55
Figure 3. MicroRNA (miRNA) Biogenesis
RNA polymerase II transcribes the DNA to produces a pri-miRNA. The pri-miRNA is cleaved into a pre-miRNA by the microprocessor complex consisting of the DiGeorge
syndrome critical region 8 (DGCR8) protein and RNase III Drosha enzyme. The pre-miRNA moves into the cytoplasm using the exportin-5-mediated nuclear export system,
which processes the approximately 22-nt miRNA duplex by the interaction of the co-factor double-stranded, transactivation-responsive RBP with RNase III endonuclease
Dicer protein. The integration of the miRNA duplex occurs with the RNA-induced silencing complex (RISC) following binding to glycine tryptophan repeat-containing protein
and Argonaute protein, which bind to full or partial sequences in the 30 or 50 UTR of the target mRNA.
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NAs is tissue-dependent, which brings into question the suitability of
systemic delivery of miRNA mimics or antagonists, as has been
mostly conducted in experimental studies. Targeted delivery systems
for drugs are often considered to be alternative approaches; however,
this approach would be further complicated by the heterogeneous
clinical manifestations in patients with sepsis, as well as non-opti-
mized delivery technology.
Recent experimental investigations have revealed that miRNA
expression levels are correlated with septic complications and thera-
peutic interventions in sepsis patients.43,78,102–113 The upregulation of
miR-511 induced by glucocorticoid administration inhibited the TNF
receptor TNFR1, and therefore decreased its sensitivity to TNF-a in
SPRET/Ei mice.78 Likewise, in an LPS-induced sepsis model, dexa-
methasone administration downregulated miR-155 expression in56 Molecular Therapy: Nucleic Acids Vol. 21 September 2020the liver and reduced the production of pro-inflammatory cyto-
kines.105,114 miRNAs have also been implicated in cortisol non-
responsiveness, which may occur during the course of treatment.
This phenotype of steroid resistance is associated with changed
expression of the glucocorticoid receptor a, an isoform of the cortisol
receptor. The mentioned isoform was remarkably downregulated in
patients with sepsis, which may be related to miR-124, which was
elevated 3-fold upon exposure to glucocorticoids.106
After exposure to systemic LPS, the body switches to a state of toler-
ance, which prevents prolonged pro-inflammatory reactions. During
induction of LPS tolerance, translation and transcription of acute in-
flammatory genes can be silenced, which is mediated by different
miRNAs in vitro.115 Modulation of this tolerance process can be
disturbed by miR-146a overexpression in sepsis models.116 Differen-
tial expression of sepsis-related miRNAs has implicated a variety of
Table 2. Selected MicroRNAs Involved in Sepsis
MicroRNAs
Expression in
Sepsis Key Points of Investigation
Model (In Vitro, In Vivo,
Human) Sample Type Sample Size Ref.
miR-150 down
miR-150 levels in both leukocytes and plasma
correlated with the severity of sepsis and
could be used as a marker of early sepsis humans plasma, leukocytes 8 140
plasma ratio of levels of miR-150/IL-18 could
be used for assessing the severity of sepsis
miR-125b down
polymicrobial sepsis (CLP) decreased miR-
125b levels in circulation and in myocardium
mice heart – 231
miR-205b down
serum miR-205b concentrations were
decreased in the LPS group compared to
control group, but in lungs, spleen, and liver
the decrease was not significant
mice serum, organs – 232
miR-23a-5p down
serum miR-23a-5p was increased after LPS
injection
rats serum, lung tissues – 102
miR-21-3p up
miR-21-3p controls sepsis-related cardiac
dysfunction through modulating SORB
in vivo plasma 46 233
miR-23b down
LPS downregulates miR-23b expression in
human vascular endothelial cells (VECs);
upregulation of miR-23b inhibited the
expression of NF-kB, TNF-a, IL-6, ICAM-1,
E-selectin and vascular cell adhesion
molecule-1 (VCAM-1)
in vitro
vascular endothelial
cells
– 234
miR-375 down
miR-375 can block the JAK2-STAT3 pathway
and modulate the level of miR-21 involved in
the regulation of late-stage sepsis
in vivo blood 33 235
miR-342-5p down – humans plasma, leukocytes 8 140
miR-182 down – humans plasma, leukocytes 8 140
miR-146a down – humans serum
50 + 30
(SIRS)
24
miR-223 down – humans serum
50 + 30
(SIRS)
24
miR-130a down – humans PBMCs 60 149
miR-31 down
miR-31 downregulation in CD4+ T cells
contributes to immunosuppression in sepsis
patients via promoting TH2 skewing
humans T cells 23 236
miR-15a down – humans plasma 62 30
miR-27a down
miR-34a, miR-15a, and miR-27a are
correlated with shock development in severe
sepsis patients; they also target cell cycle
regulation, apoptosis, cell layer permeability,
and inflammatory pathways
humans plasma 62 30
miR-25 down
a correlation between levels of miR-25 and the
severity of sepsis was observed; surviving
patients had higher levels of this biomarker
compared with non-surviving subjects;
decreased levels of miR-25 were associated
with the concentrations of oxidative stress
indicators in sepsis
humans blood
70 + 30
(SIRS)
28
miR-146a, miR-181a, miR-
584
down – humans PBMCs 32 80
miR-146a down
miR-146a gene polymorphism rs2910164 is
associated with the risk of severe sepsis
humans PBMCs 226 237
miR-146a down – humans plasma
14 + 14
(SIRS)
238
(Continued on next page)
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Table 2. Continued
MicroRNAs
Expression in
Sepsis Key Points of Investigation
Model (In Vitro, In Vivo,
Human) Sample Type Sample Size Ref.
miR-499-5p down – humans serum 166 26
miR-122 down – humans serum 166 26
miR-193b down – humans serum 166 26
miR-150 down – humans PBMCs 23 + 22 29
miR-342 down – humans PBMCs 23 + 22 29
miR-3173-5p down – humans PBMCs 23 + 22 29
miR-181b down
miR-181b regulates NF-kB-mediated
endothelial cell activation and vascular
inflammation in response to pro-
inflammatory stimuli
in vitro
plasma
26 SP
139
in vivo
36 SP +
ARDS
let-7a down – mice lung – 239
miR-129-5p down – mice lung – 239
miR-218 down – mice lung – 239
miR-21 up
miR-21 is involved in the regulation of late
sepsis
in vivo blood 33 235
miR-155 up
miR-155 induced an elevated percentage of
CD39+ regulatory T cells, leading to
immunosuppression
in vivo blood 60 97
miR-15a up
upregulated miR-15a downregulated the LPS-
induced inflammatory pathway
humans serum 46 136
miR-16 up
upregulated miR-16 downregulated the LPS-
induced inflammatory pathway
humans serum 46 136
miR-15a
up
serum miR-15a/miR-16 levels were
significantly elevated in sepsis/SIRS patients
when compared to healthy controls
humans serum 166 + 32 27
miR-16
miR-574-5p up
serum level was correlated with the death of
sepsis patients
humans serum 142 103the combined analysis of miR-574-5p, SOFA
scores, and the sepsis stage on the day of
diagnosis provided a good predictor for sepsis
prognosis
miR-297 up
serum miR-297 level was higher in survivors
than non-survivors among septic patients
humans serum 142 103
miR-223 up – humans serum 166 26
miR-19a up – in vitro B cells
38 + 26
(SIRS)
240
miR-486 up – humans plasma, leukocytes 8 140
miR-34a up – humans plasma 62 30
miR-145 up – humans PBMCs 32 80
miR-143 up – humans PBMCs 32 80
miR-182 up – humans PBMCs 32 80
miR-486 up – humans PBMCs 32 80
miR-1308 up – humans PBMCs 32 80
miR-4772 up – humans blood 23 +22 29
miR-143 up
serum miR-143 levels were significantly
higher in sepsis than in SIRS and healthy
controls
humans serum
103
241
95
miR-133a up
there was a correlation between the levels of
miR-133a and sepsis severity
humans, mice serum 138 137
(Continued on next page)
58 Molecular Therapy: Nucleic Acids Vol. 21 September 2020
www.moleculartherapy.org
Review
Table 2. Continued
MicroRNAs
Expression in
Sepsis Key Points of Investigation
Model (In Vitro, In Vivo,
Human) Sample Type Sample Size Ref.
miR-4772 up – humans blood 23 + 22 29
let-7d up
the levels of these biomarkers were elevated in
whole blood after LPS injection
mice blood, organs – 242
miR-15b up
the levels of these biomarkers were elevated in
whole blood after LPS injection
mice blood, organs – 242
miR-16 up
the levels of these biomarkers were elevated in
whole blood after LPS injection
mice blood, organs – 242
miR-25 up
the levels of these biomarkers were elevated in
whole blood after LPS injection
mice blood, organs – 242
miR-92a up
the levels of these biomarkers were elevated in
whole blood after LPS injection
mice blood, organs – 242
miR-103 up
the levels of these biomarkers were elevated in
whole blood after LPS injection
mice blood, organs – 242
miR-107 up
the levels of these biomarkers were elevated in
whole blood after LPS injection
mice blood, organs – 242
miR-451 up
the levels of these biomarkers were elevated in
whole blood after LPS injection
mice blood, organs – 242
miR-15a up
the levels of these biomarkers were elevated in
lung
mice blood, organs – 242
miR-16 up
the levels of these biomarkers were elevated in
lung
mice blood, organs – 242
miR-21 up
the levels of these biomarkers were elevated in
lung
mice blood, organs – 242
miR-146a up
the levels of these biomarkers were elevated in
lung
mice blood, organs – 242
miR-155 up
the levels of these biomarkers were elevated in
lung
mice blood, organs – 242
miR-223 up
the levels of these biomarkers were elevated in
lung
mice blood, organs – 242
miR-195 up
miR-195 was elevated in lung and liver of
sepsis-induced mice
mice lung, liver – 7
miR-27a up
miR-27a induces an inflammatory response
in sepsis
mice lung – 239
miR-143 up mice lung – 239
miR-153 up mice lung – 239
miR-21 up
miR-21 increased in early sepsis and showed a
sustained increase until late sepsis
mice bone marrow – 96
miR-181b up
miR-181b increased in early sepsis and
showed a sustained increase until late sepsis
mice bone marrow – 96
miR-16 up miRNAs upregulated after CLP mice blood – 243
miR-17 up miRNAs upregulated after CLP mice blood – 243
miR-20a/b up miRNAs upregulated after CLP mice blood – 243
miR-26a/b up miRNAs upregulated after CLP mice blood – 243
miR-106a/b up miRNAs upregulated after CLP mice blood – 243
miR-195 up miRNAs upregulated after CLP mice blood – 243
miR-451 up miRNAs upregulated after CLP mice blood – 243
miR-29a –
miR-29a induces apoptosis of monocytes via
targeting STAT3 during sepsis
mice THP-1 cells – 101
(Continued on next page)
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Table 2. Continued
MicroRNAs
Expression in
Sepsis Key Points of Investigation
Model (In Vitro, In Vivo,
Human) Sample Type Sample Size Ref.
miR-30a –
miR-30a inhibits MD-2 expression by
targeting STAT1 in human monocytes
mice THP-1 cells – 244
miR-146 –
the transfection of miR-146a reduces the
sepsis-induced cardiac dysfunction through
inhibiting inflammatory cell infiltration, NF-
kB activation, and inflammatory cytokine
production by targeting TRAF6 and IRAK
mice H9C2 and J774 cells – 83
miR-150 –
reduced miR-150 serum concentrations are
associated with an unfavorable outcome in
patients with critical illness, independent of
the presence of sepsis
humans serum 138 42
miR-223 –
it has been found that this biomarker does not
appropriate in predicting sepsis
humans, mice serum 137 43
miR-122 –
serum miR-122 levels correlated with short-
term mortality in sepsis patients and are a
potential biomarker for sepsis and ARDS
humans serum 232 104
miR-15a
–
the expression levels of miR-193b, miR-122,
miR-483-5p, and miR-15a in the sepsis non-
survivors were significantly higher than those
in the sepsis survivors, and the levels of miR-
223 and miR-16 were significantly lower
humans serum 214 245
miR-16
miR-122
miR-193b
miR-483-5p
miR-223
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inmiRNAs in endotoxin tolerance is observed predominantly inmac-
rophages and involves miR-155 and miR-146a.117,118 Recent evidence
has suggested that miRNAmodulation during LPS tolerance involves
the TLR-NF-kB-cytokine pathways.119–121
Some therapies that have been tested for sepsis involve the regulation
of miRNAs. These miRNAs have been mostly correlated with path-
ways involved in innate immunity in animals122,123 and cellular
models.124,125 Flavonoids are well-studied anti-inflammatory com-
pounds. It has been recently shown that the flavonoid apigenin in-
hibits LPS-mediated expression of miR-155 inmacrophages, resulting
in upregulation of the anti-inflammatory modulators MAD-related
protein 2 and forkhead box O3a in vitro.125 In a murine model of
sepsis, similar protective effects were shown when an apigenin-rich
diet significantly decreased TNF-a and miR-155 expression in the
mouse lungs.125 Recently, stem cell therapy has attracted further
attention for sepsis. In vivo investigations showed that mesenchymal
stem cells (MSCs) prolong survival in mice with sepsis induced by
cecal ligation and puncture (CLP) through downregulating miR-
143.124,126 In septic mice treated with MSCs, microarray analysis
revealed that there were 77 miRNAs with more than 1.5-fold differ-
ential expression.122 This was accompanied by a decreased inflamma-
tory response as well as less apoptosis.122 Experimental sepsis models
that were treated with the 20-hydroxyeicosatetraenoic acid (20-
HETE) analog N-(20-hydroxyeicosa-5Z,14Z-dienoyl)glycine showed
effects on the expression of miR-297, miR-223, and miR-150.123 It60 Molecular Therapy: Nucleic Acids Vol. 21 September 2020was suggested that these miRNAs were downregulated, resulting in
inhibition of the myeloid differentiation primary response gene 88
(MyD88)/NF-kB pathway.127
Assessment of the ability of miRNAs to function as therapeutic agents
in sepsis has mainly employed two approaches: use of miRNAmimics
or antagomirs. An antagomir is a small synthetic RNA that is perfectly
complementary to the specific miRNA target and inhibits Ago2-
mediated cleavage. Among all miRNAs, miR-146a has been the
most widely investigated. Through targeting TRAF6 and IRAK1,
miR-146a reduced cardiac dysfunction in septic mice.83 In vivo deliv-
ery of a miR-146a antagomir using jetPEI instillation into the airways
of septic mice suppressed the generation of pro-inflammatory cyto-
kines and ameliorated the injury to lung tissue.128 It was recently re-
ported that this miRNA also inhibited the in vitro differentiation of
human CD4+ T lymphocytes via affecting protein kinase C
(PRKC).129 Other miRNAs, such asmiR-195, miR-142-3p, and
miR-124, have also been reported to be beneficial in preventing
apoptosis, inflammation, and organ injury in sepsis
models.7,116,130,131 The induction of miR-126 expression using
CTEC-0214, a stromal cell-derived factor 1a analog, preserved the
endothelial cell barrier integrity and decreased pulmonary vascular
leakage.132
Non-coding RNAs as Biomarkers in Sepsis
The detection of non-coding RNAs within various organs or tissues
may be useful as biomarkers for sepsis, as well as sepsis-associated
Figure 4. The Association of lncRNAs and miRNAs with the Pathophysiology of Sepsis
eNOS, endothelial nitric oxide synthase; HuR, human antigen R; CISH, cytokine-inducible SH2-containing protein; MDSC, myeloid-derived suppressor cell; IRAK, IL-1
receptor-associated kinase; JNK, c-Jun N-terminal kinase; TRAF6, TNF receptor-associated factor 6; MyD88, myeloid differentiation primary response gene 88; BMPR2,
bone morphogenetic protein receptor type II; NF-kB, nuclear factor kB; IkB, inhibitor of kB; SOX6, sex-determining region Y box 6; Sirt1, sirtulin 1; Pim1, proto-oncogene
serine/threonine-protein kinase; BMAL1, brain and muscle ARNT-like 1; PDCD4, programmed cell death 4; PGC1A, PPARg (peroxisome proliferator-activated receptor g)
co-activator 1A; PRKC, primary rat kidney cell.
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clinical sample from sepsis patients for detecting non-coding RNAs,
because it contains leucocytes, plasma, and serum. The existence of
extracellular miRNAs within blood can be rapidly quantified in a clin-
ical setting, unlike microbial culture, which is more time-
consuming.63 Therefore, this ease of use has encouraged more studies
of whether miRNAs could be diagnostic biomarkers for sepsis. As
mentioned earlier, various miRNAs are expressed differentially in
sepsis. For instance, miR133a, miR122, and miR-16 were elevated
in the serum of patients with sepsis,136–138 while other miRNAs,
including miR-181b and miR-25, were reduced.28,139 Additionally,
one recently performed study indicated that the clinical accuracy of
the measurement of miRNA-25 for the diagnosis of sepsis was better
than C-reactive protein (CRP) and procalcitonin (PCT) (area under
the receiver operating characteristic [ROC] curve = 0.806, 0.676,
and 0.726 for miRNA-25, CRP, and PCT, respectively).28 The down-
regulation of miRNA-25 levels was associated with the severity of
sepsis (Sequential Organ Failure Assessment [SOFA] score), CRP,
as well as PCT levels.28 Moreover, a similar investigation revealed
that at a cutoff point set at 1.89, miR-233 provided a sensitivity of
80% and a specificity of 100%, while at a cutoff point set at 2.98,
miR-146a provided a sensitivity of 63.3% and a specificity of
100%.24 With this high sensitivity and specificity, these miRNAscould be used as novel biomarkers for sepsis.24 miRNAs have also
been shown to be correlated with the prognosis of sepsis patients. Va-
silescu et al.140 reported that miR-150 concentrations were signifi-
cantly decreased in plasma samples from patients with sepsis, and
they were related to the severity of the disease as assessed by the
SOFA scores. miR-150 was shown to control the expression of c-
Myb in vivo in a dose-dependent manner over a narrow range of c-
Myb concentrations, and this influenced lymphocyte responses and
differentiation,141 which supports the importance of miR-150 down-
regulation in patients with sepsis. A study carried out by Wang
et al.103 revealed that the combination of sepsis SOFA scores and
miR-574-5p expression levels could predict the mortality of patients
with sepsis with 91.84% specificity and 78.13% sensitivity. Thus, miR-
NAs may play a crucial role in improving sepsis prognosis and diag-
nosis in affected individuals.
Cardiac dysfunction induced by sepsis is characterized by a reduced
ejection fraction and disturbed myocardial contractility.142 However,
the pathophysiology of myocardial dysfunction induced by sepsis is
not completely understood, and there is no effective medication to
reverse sepsis-mediated myocardial dysfunction.143 Numerous
studies have suggested that miRNAs may play an important role in
sepsis-mediated cardiac dysfunction. For instance, in a experimentalMolecular Therapy: Nucleic Acids Vol. 21 September 2020 61
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tory responses at several levels, and resulting in the induction of
myocardial dysfunction.144 In addition, miR-155 inhibition protected
against LPS-mediated cardiac dysfunction.145 Moreover, miR-146a
was able to decrease sepsis-mediated cardiac dysfunction through
preventing the activation of NF-kB, as well as decreasing the infiltra-
tion of inflammatory cells.83 It has been recently shown that LPS in-
hibited the expression of miR-499, resulting in cardiomyocyte
apoptosis via the Bcl-2 family pathway.146 lncRNAs have been shown
to be implicated in the sepsis-induced cardiac dysfunction process.
The lncRNA HOTAIR was observed to be considerably upregulated
and it positively modulated NF-kB activation and p65 phosphoryla-
tion in cardiomyocytes taken from septic mice.14 Therefore, several
non-coding RNAs have been shown to induce sepsis-mediated car-
diac dysfunction. These agents may deserve to be considered as diag-
nostic biomarkers for patients with sepsis-mediated cardiac
dysfunction.
Thrombocytopenia is an important abnormality that occurs in severe
sepsis patients.147,148 It has been recently shown that septic patients
with thrombocytopenia had elevated concentrations of IL-18 and
some miRNAs, as well as reduced miR-130a expression, suggesting
that miRNAs could be implicated in sepsis-related thrombocytopenia
and thus function as a biomarker.149 Additionally, a study by Wang
et al.138 indicated that levels of miR-122 were higher in the abnormal
coagulation group compared to normal coagulation patients. Overall,
it is unclear how miRNAs influence coagulation, and further investi-
gation is required to understand whether miRNAs can be coagulop-
athy indicators.
Inflammation of the endothelium has an essential role in sepsis path-
ogenesis.150 It was shown that LPS-mediated endothelial dysfunction
was induced by the Slit2-Robo4 pathway, and Slit2 downregulation
decreased miR-218 expression.151 Furthermore, miR-147b has been
implicated in endothelial protection via the degradation of the
mRNA for ADAM15 (a regulator of endothelial permeability).152
Altogether, the data suggest that different miRNAs could be consid-
ered to be novel indicators for sepsis-related cardiac and endothelial
dysfunction.Exosome Biogenesis
Multivesicular bodies (MVBs) are late-stage endosomes containing
numerous intraluminal endosomal vesicles, some of which are tar-
geted for lysosomal degradation, and others for cell membrane inte-
gration followed by the extracellular release of the vesicles. The
smaller vehicles (30–120 nm in diameter) are known as exosomes,
while the larger vehicles (120–1,000 nm in diameter) are called micro-
vesicles.153–155 The exosomes contain ubiquitinated proteins that
have been loaded by an “endosomal sorting complex required for
transport” (ESCRT) or other ESCRT-independent mechanisms
(Figure 5).156 Electron microscopy images exhibit a “cup-shaped”
morphology for exosomes isolated by differential
ultracentrifugation.15762 Molecular Therapy: Nucleic Acids Vol. 21 September 2020The composition of exosomes has been found to be uniquely dispa-
rate and complex, so that 194 lipids, 4,563 proteins, 764 miRNAs,
and 1,639 mRNAs have been cataloged to be present inside exosomes
isolated from various organisms, based on the database ExoCarta
(version 4; http://www.exocarta.org).158 The exosomal proteins
mainly belong to the families of heat shock proteins (heat shock
cognate 70 [HSC70]), membrane transporters, and fusion proteins
(annexins, flotillin, and GTPases), MVB biogenesis proteins (tumor
suppressor gene 101 [TSG101] and alix), tetraspanins (CD81,
CD63, and CD9) lipid-related proteins, and phospholipases.157,159
There are certain mRNAs commonly found inside exosomes that
code for proteins, importantly including CD81, CD63, and tetraspa-
nins. Exosomal lipids are mainly sphingolipids, cholesterol, bisphos-
phates, and phospholipids, which have been detected in exosomes
secreted by different cells, such as mast cells and dendritic cells,160 re-
ticulocytes,161 and B lymphocytes.162 Some specific exosomal lipid
components, including phosphatidylserine (PS)163 and prostaglan-
dins,164 have been reported to be involved in the biological function
of exosomes. Exosomal miRNAs and mRNAs play a role as carriers
for genetic information. Despite the degradation of most exosomal
RNAs into <200-nt-long RNA fragments, several full-length RNAs
can be taken up into cells through an endocytosis process and influ-
ence their protein expression. Exosomal miRNA expression has been
associated with some diseases, including cancer, indicating the poten-
tial of exosomal miRNAs to act as biomarkers for cancer diag-
nosis.165–167 miRNAs have been frequently reported to be present
in exosomes isolated from body fluids such as saliva and urine,168
thereby encouraging the use of exosomal miRNAs as novel
biomarkers.
Exosomes and EVs in Sepsis
Efficient intercellular communication is necessary in order to coordi-
nate the inflammatory responses of immune cells. Chemokines, cyto-
kines, and cell surface receptors are all involved in communications
between immune cells. Mounting data indicate that immune cells
are able to signal through the release of exosomes that carry various
biological molecules, and that can be taken up by recipient cells,
thereby altering their function.41,169–178
Ying et al.179 showed that it was the miRNAs within exosomes that
were primarily responsible for the biological effects.41,180 Further-
more, some beneficial immunomodulatory effects of plasma-derived
exosomal miRNAs have been recently demonstrated in patients with
sepsis (Table 3; Figure 6).181 Therefore, exosomal miRNAs have been
proposed to be responsible for the anti-apoptotic effects observed in T
lymphocytes by addition of sepsis exosomes (Sepsis-Exos). However,
there are still complicated relationships operating between miRNAs
and their mRNA targets. Theoretically, one miRNA is capable of tar-
geting more than one mRNA, and vice versa, and there could be more
than one miRNA able to target any individual mRNA sequence.182
Hence, bioinformatics analysis of the Sepsis-Exos differentially ex-
pressed (DE) miRNAs was carried out, suggesting that the
apoptosis-associated guanosine monophosphate-protein kinase G
(cGMP-PKG) pathway was involved.
Figure 5. Exosome Biogenesis
Endocytosis at a lipid raft occurs by either a clathrin-dependent pathway or a clathrin-independent pathway. The endocytic vesicles contain signaling proteins, growth factor
receptors, and oncoproteins, together with normal membrane proteins, including tetraspanins (e.g., CD9, CD63, and CD81), MHC I and II, and adhesion molecules (e.g.,
cadherins, integrins). Exosome biogenesis occurs via the endosomal network in the endosomal sorting complexes needed for ESCRT-independent or ESCRT-dependent
pathways. Inward budding of multi-vesicular bodies (MVBs) produces intra-luminal vesicles (exosomes). Several cytoplasmic molecules (e.g., heat shock proteins, ubiq-
uitin-related proteins,mRNAs,miRNAs, cytoskeleton proteins) and nuclear molecules (e.g., lncRNAs, transcription factors, DNAs) can be loaded intoMVBs via stage-specific
pathways, some of which are more or less specific for the state of sepsis. Moreover, plasma membrane fusion of MVBs leads to release of exosomes by exocytosis.
Numerous Rab GTPases (such as Rab11/35, Rab7, and Rab27) are contained in secreted exosomes. rER, rough endoplasmic reticulum; sER, smooth endoplasmic re-
ticulum.
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isolated during sepsis. miRNA-125b was detected in endothelial pro-
genitor cell-derived exosomes in a mouse model, and its expression
level was also downregulated during sepsis.45 It was recently shown
that some miRNAs in endothelial progenitor cell-derived exosomes
(miR-34a, miR-27a, and miR-15a) had different expression levels in
the plasma of sepsis patients.30
In one study, Real et al.181 assessed the mRNAs and miRNAs associ-
ated with inflammatory responses, as well as redox metabolism in the
exosomes of septic shock patients. In comparison to healthy subjects,
exosomes from sepsis patients had significant alterations in 65
different exosomal miRNAs. Twenty-eight miRNAs were expressed
differentially, both at recruitment and after 7 days, with similar ki-
netics (10 miRNAs downregulated and 18 upregulated). In compari-
son to control individuals, the pathways enriched by the miRNAs of
sepsis patients were correlated with inflammatory responses. The
comparison of miRNA levels in sepsis patients with their length of
survival in the hospital implicated pathways associated with cell cycle
modulation. At recruitment, sepsis was correlated with elevations in
mRNA expression associated with redox metabolism (myeloperoxi-dase, 64-fold; peroxiredoxin 3 [PRDX3], 2.6-fold; superoxide dismut-
ase 2 [SOD2], 2.2-fold) and redox-responsive genes (forhead box pro-
tein M1 [FOXM1], 21-fold; SELS, 16-fold; glutaredoxin 2 [GLRX2],
3.4-fold). Myeloperoxidase mRNA expression remained elevated af-
ter 7 days (65-fold). Exosomes from septic shock patients contain
mRNAs and miRNAs associated with pathogenic processes, such as
cell cycle modulation, oxidative stress, and inflammatory response.
Overall, exosomal transport represents a novel pathway for intercel-
lular communication during sepsis.
Studies have suggested that exosomal miRNAs could modulate
inflammation by regulating target proteins in different signaling path-
ways. miR-223 directly targets STAT3 to regulate pro-inflammatory
cytokines. Alternatively, IL-6 triggered by stimulation of TLR/NF-
kB could promote miR-223 downregulation; therefore, IL-6 could
form a positive regulatory loop for the production of pro-inflamma-
tory cytokines.183 As a result, when exosomes containing miR-223,
which were derived from MSCs, were administered to animal models
of sepsis, they could downregulate the expression of its target genes
and suppress inflammatory response in macrophages. It has been
shown that pro-inflammatory and anti-inflammatory miRNAs,Molecular Therapy: Nucleic Acids Vol. 21 September 2020 63
Table 3. Exosomes and Their Cargos in Sepsis
Cargo Detection Methods Model Note Ref.
Protein (ATF3) differential centrifugation + western blot
humans (urine),
mice
urinary exosomal ATF3 is an early diagnostic
biomarker for sepsis-induced acute kidney
injury
185
Protein (SPTLC3)
one-step ultracentrifugation using OptiPrep +
mass spectrometry using Q Exactive Plus
humans
(plasma)
SPTLC3 is involved in sphingolipid metabolism,
with a negative correlation with the progression
of sepsis
187
Proteins ExoQuick exosome precipitation
humans
(plasma)
proteomic profile analysis of sepsis-derived
exosomes and LPS-stimulated, monocyte-
derived exosomes exhibited downregulation of
several important protein networks, including
immune response
188
miRNA (miR-126) centrifugation + ExoQuick mice (serum)
levels of miR-126 in serum exosomes isolated
from HSPA12B-deficient (HSPA12B/) septic
mice were significantly lower than those for
wild-type septic mice 186
felivery of miR-126 containing exosomes
significantly improved cardiac function and
vascular permeability in HSPA12B/ septic mice
miRNA (miRNA-125b) – mice (serum)
miRNA-125b in endothelial progenitor cell-
derived exosomes was also downregulated
during sepsis
45
miRNA (miR-155 and miR-146a) differential centrifugation mice (serum)
miR-146a inhibited while miR-155 promoted
endotoxin-induced inflammation
miRNA (miR-34a, miR-27a, and miR-15a) ExoQuick exosome precipitation solution
humans
(plasma)
miR-34a, miR-27a, and miR-15a in the
endothelial progenitor cell-derived exosomes
had different expression levels in sepsis patients
30
miRNA (miR-223)
centrifuged + filtering through 0.2 mm + Tris/
EDTA
mice (serum)
exosomal miR-223 plays an essential role for
MSC-induced cardioprotection in sepsis
183
miRNA (miR-126-3p, miR-122-5p, miR-146a-
5p, miR-145-5p, miR-26a-5p, miR-150-5p,
miR-222-3p, and miR-181a-5p)
differential ultracentrifugation mice (serum)
EVs of septic animals play an important role in
inflammation, and EV-associated miRNAs
likely mediate the cytokine production via
TLR7-MyD88 signaling
189
miRNA (miR-122-5p, miR-125b-5p, miR-
1260a, miR-1262, miR-127-3p, miR-1290, miR-
1298-5p, miR-146a-5p, miR-151a-3p, miR-16-
5p, miR-1825, miR-192-5p, miR-193a-5p, miR-
221-3p, miR-25-3p, miR-26a-5p, miR-301a-3p,
miR-320b, miR-339-3p, miR-340-5p, miR-532-
3p, miR-720, miR-744-5p, miR-885-5p, miR-
92a-3p)
ultracentrifugation + western blot +
nanoparticle-tracking analysis device + nano
flow cytometry
humans
(plasma)
– 181
mRNA (myeloperoxidase [MPO], PRDX3,
SOD2, FOXM1, SELS, and GLRX2)
ultracentrifugation + western blot +
nanoparticle-tracking analysis device + nano flow
cytometry
humans
(plasma)
– 181
mRNA (DNMT1, DNMT3A, DNMT3B) centrifugation
humans
(plasma)
EV-DNMT mRNAs load, when coupled with
total plasma EV number, may be a novel method
to diagnose septic shock
190
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responses. Alexander et al.184 showed that dendritic cells released exo-
somes containing miR-155 and miR-146a, and that could be taken up
by other recipient dendritic cells, thereby reprogramming the cellular
response to endotoxin. Exosome-delivered miR-155 increased the
expression of inflammatory genes, whereas miR-146a decreased it.
They showed that miR-155 and miR-146a could pass between
immune cells in vivo, and that exosomal miR-146a inhibited endo-64 Molecular Therapy: Nucleic Acids Vol. 21 September 2020toxin-induced inflammation in mice, while, alternatively, miR-155
promoted the inflammatory response.
In another study, Wang et al.183 evaluated the effect of treating sepsis-
induced mice with miR-223-knockout (KO) exosomes obtained from
knockout mice, and they showed that the mice had higher levels of
Sema3A and STAT3 (targets of miR-223) than did mice treated with
wild-type (WT) exosomes. These exosomal proteins could be
Figure 6. Schematic Representation of Exosome Functions in Sepsis
Exosomes and their contents (i.e., miRNAs, mRNAs, and proteins) could be involved in the pathogenesis of sepsis. In this regard, these nanovesicles and their cargos could
increase apoptotic cell death in various cells and tissues, and reduce apoptotic cell clearance by phagocytes, such as macrophages and dendritic cells. Disturbance of the
phagocytic removal of apoptotic cells has the potential to release toxic and proinflammatory contents due to secondary necrosis, and it could increase tissue injury and
mortality.
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more cell death. In contrast, WT exosomes, which had higher levels of
miR-223, couldbe delivered to cardiomyocytes, causing downregulation
of Sema3AandStat3. Therefore, they concluded that exosomalmiR-223
could play a role in MSC-induced cardioprotection in sepsis patients.
Panich et al.185 investigated possible biomarkers in urine samples
from patients with early sepsis-induced acute kidney injury. They
found that urinary exosomal ATF3 could be an interesting early diag-
nostic biomarker for sepsis-induced acute kidney injury.
Zhang et al.186 investigated the cardioprotective mechanism of
HSPA12B in sepsis-induced cardiovascular dysfunction. They found
that the levels of miR-126 in serum exosomes isolated from
HSPA12B/ septic mice were lower than those fromWT septic mice.
Interestingly, delivery of miR-126 containing exosomes improved car-
diac function, decreased immune cell infiltration in the myocardium,
and improved vascular permeability inHSPA12B/ septicmice.There-
fore, they showed that HSPA12B could improve endothelial function in
sepsis and suggested that exosomes containingmiR-126 could play a role
in the cardiovascular protective mechanisms in polymicrobial sepsis.
Xu et al.187 used a one-step ultracentrifugation process using an Op-
tiPrep density gradient medium to extract exosomes from humanplasma samples with volumes as small as 300 mL. They obtained
the exosomal proteomic profile from septic patient blood samples
at six time points after diagnosis. Among the 238 proteins, the protein
SPTLC3, which is involved in sphingolipid metabolism, showed a
negative correlation with disease progression measured by body tem-
perature and CRP levels. The results showed that SPTLC3 may be
involved in the development of sepsis and could be a biomarker to
monitor the clinical progression of sepsis.
Wisler et al.188 analyzed the proteomic pathways in monocyte-derived
exosomes isolated frompatients suffering from surgical sepsis to identify
possible immunoregulatory functions. They compared the proteomic
networks in exosomes derived from LPS-stimulated monocytes with
those isolated from patients with surgical sepsis. Proteomic analysis
showed that 17 proteins were downregulated, while 1 was upregulated
in sepsis-derived exosomes, whereas 14 were downregulated and 1 was
upregulated in the LPS-stimulated exosomes. Functional enrichment
analysis showed that the downregulated processes included biogenesis,
localization, and metabolic and cellular pathways, in addition to those
involved in the immune system. InLPS-stimulatedmacrophages, similar
metabolic and cellular processes were downregulated. Human mono-
cytes treatedwith sepsis-derived exosomes, or exosomes fromLPS-stim-
ulatedmonocytes, suggested that circulating exosomes could be involved
in systemic signaling and immunomodulation during sepsis.Molecular Therapy: Nucleic Acids Vol. 21 September 2020 65
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septic mice could increase inflammation and cytokine production.
They found that the effects of the EVs were not affected by polymyxin
B (an endotoxin inhibitor), but were significantly inhibited by anti-
miR inhibitors designed against miR-34a, miR-122, and miR-146a.
The cytokine production induced by septic EVs was lower in
TLR7/ or MyD88/ cells. Therefore, EV-associated miRNAs
were suggested to mediate cytokine production via TLR7-MyD88
signaling. DNAmethyltransferases (DNMTs) are conserved enzymes
that are epigenetic regulators of gene expression. The balance between
DNMTs involved in DNA repair (DNMT1) and the de novo DNMTs
(DNMT3A and DNMT3B) may change during serious diseases.
Dakhlallah et al.190 investigated the mRNAs coding for DNMTs in-
side EVs as prognostic markers for septic shock. Comparison of
EV-DNMT1 (maintenance methylation) with EV-DNMT3A+-
DNMT3B (de novomethylation) correlated with the severity of sepsis,
EVs obtained from septic shock patients carried more total DNMT
mRNAs and more DNMT3A+DNMT3B mRNAs than did control
EVs. Total circulating (plasma) EVs also correlated with sepsis
severity. Therefore, the EV-DNMT mRNA load, coupled with total
number of plasma EVs, could be a method to diagnose septic shock
in patients at intensive care unit (ICU) admission, and could offer op-
portunities to more precisely intervene with standard therapy or test
more advanced approaches.
Human umbilical cord MSC-derived exosomes (hucMSC-Exs) have
been investigated for the repair of acute kidney injury (AKI) caused
by cisplatin or ischemia/reperfusion injury. Zhang et al.191 investi-
gated the benefits of hucMSC-Exs in sepsis. They found that treat-
ment with hucMSC-Exs ameliorated morphological damage and in-
hibited renal tubular cell apoptosis. Treatment with hucMSC-Exs
improved the survival of mice with sepsis. The effects of hucMSC-
Exs were proposed to be via the inhibition of NF-kB signaling and
the lessening of pro-inflammatory responses.
Although the triggering of thrombotic pathways is thought to inhibit
bacterial dissemination throughout the body by shutting down blood
flow, thrombosis may also result in excessive consumption and acti-
vation of coagulation components. Because EVs have shown a pro-
coagulant activity, they may be implicated in the pathophysiology
of disseminated intravascular coagulation (DIC) in patients with
sepsis.192 DIC is recognized to be an extreme symptom in sepsis,
and its onset is correlated with increased mortality. DIC is character-
ized by the massive accumulation of thrombi within the microcircu-
lation, as well as excessive consumption of platelets and coagulation
components. Approximately 35% of patients with sepsis develop
DIC.193 At present, the management of sepsis, which is complicated
by DIC, requires treatment of the underlying infection with broad-
spectrum antibiotics and surgical control of the infection source,194
accompanied by support for organ function. Despite many attempts,
other therapeutic approaches have not yet shown any statistical suc-
cess in large-scale clinical trials. An early quantification of the risk for
developing DIC would be highly useful in patients who present in the
initial stages of sepsis. Therefore, EV assays may contribute to this risk66 Molecular Therapy: Nucleic Acids Vol. 21 September 2020assessment, and also aid in identification of novel targets for therapy.
EVs also exhibit direct pro-coagulant activities due to the exposure of
PS on their surface. PS is a cell membrane phospholipid that helps the
function of tissue factor (TF) and coagulation enzymes, and is a major
initiator of the coagulation cascade.195,196 In sepsis, pro-coagulant
EVs are principally secreted by monocytes (MEVs), endothelial cells
(EEVs), and platelets (PEVs).197 TF serves as a primary initiator of the
coagulation cascade, while PS is a catalyst for the activation of coag-
ulation components. Both functions make this EV subset a likely fac-
tor for the dissemination of the pro-coagulant phenotype during
sepsis.198,199 As mentioned above, PEVs are the major source of TF
in plasma.200 In addition to upregulation of TF in monocytes and
endothelial cells, and the activation of fibrinolytic and prothrombotic
pathways, blood-borne TF-positive EVs are also partly responsible for
the overall prothrombotic milieu underlying DIC.195,201
Numerous studies have suggested an indirect role of EVs as “carrier
vehicles” linking coagulation and inflammation. It has been previ-
ously proposed that the release of EVs acts as a danger signal, leading
to the transition into a pro-thrombotic phenotype.202 IL-33 has also
been implicated in the increased activity of TF in EEVs.203 Budding
and remodeling processes within the multivesicular bodies, or at
the cell membrane, are induced by highly conserved entities such as
the ESCRT.204 An increase in intracellular calcium leads to activation
of scramblase and calpain enzymes as well as the loss of symmetry in
the phospholipid bilayer leading to activation of inflammatory
cells.205,206
Patients suffering from sepsis frequently require mechanical ventila-
tion, leading to possible lung damage. EVs may be involved in sepsis-
related lung injuries, as well as other lung-associated conditions in
ICU patients. For instance, elevated EVs have been correlated with
a decreased risk of acute respiratory distress syndrome (ARDS).207
Moreover, after post-operative extubation, Mutschler et al.208 studied
the effects of mechanical ventilation on the expression of EVs in the
bronchoalveolar lavage fluid taken from both ventilated human pa-
tients and laboratory pigs. It was found that EVs bound to neutrophil
granulocytes at the pulmonary air-blood interface, suggesting that
EVs could be used as a biomarker to guide the mechanical ventilation
strategy. For instance, a predefined level of EVs could help to make
the decision whether patients with ARDS require temporary extracor-
poreal membrane oxygenation to prevent possible lung injuries being
caused by mechanical ventilation.
A stretched model of pathological pulmonary endothelial cells (which
mimics extreme tidal volume ventilation) triggered the release of EVs,
which could be counteracted by the caspase inhibitor Z-VAD209 and
was unaffected by co-treatment with calpeptin (a calpain inhibitor),
and the Rho kinase inhibitor Y-27632, LPS, and thrombin. It was
recently shown that high tidal volume ventilation in healthy mice
increased the systemic concentration of EVs derived from pulmonary
endothelial cells (CD31+) and reduced the expression of CD31 in the
lung tissue. Utilizing a stretched model of human pulmonary endo-
thelial cells, the same mechanism was proposed to explain the
www.moleculartherapy.org
Reviewshedding of CD31 and annexin V-positive EEVs.203 After intratra-
cheal instillation of EEVs into healthy animals, lung inflammation
was increased. According to proteomic analysis, several factors shared
by the various EEV populations (such as CD31) have been de-
tected.203 As mentioned above, the disintegration of the pulmonary
endothelial barrier triggers the release of EVs, which express
numerous adhesion molecules and other factors that modulate in-
flammatory events.210 It has recently been reported that an increased
level of EVs in plasma was inversely correlated with the risk for ARDS
development in a group of critically ill patients with different under-
lying pathologies. Further post hoc analysis showed that this correla-
tion was true in septic patients but not correct in non-septic
subjects.207
Moreover, systemic and endothelial activation caused by LPS and
thrombin/CD40L increased the proportion of EVs carrying CD40L
and matrix metalloproteinase 10 (MMP10) both in vivo and
in vitro. Increases in circulating CD40L and MMP10 were correlated
with increased mortality in patients with sepsis who had higher
thrombin levels.211 It was found that immunization of healthy rats
with septic rat-derived EVs decreased their arterial blood pressure.212
Additionally, inhibition of calpains seems to have a therapeutic
impact. In another investigation, the role of calpains in DIC develop-
ment was assessed in an experimental sepsis model. After suppressing
calpain activity by overexpressing its inhibitor calpastatin, they found
an increased survival benefit and attenuation of DIC.209
EVs could be useful biomarkers for the occurrence of DIC in sepsis
patients. For instance, in patients with meningococcal sepsis with or-
gan dysfunction, the circulating EVs were mostly platelet derived, and
in comparison with healthy subjects, their level was almost 15-fold
higher.213 In addition, EVs with exposed TF were reduced in sepsis
patients with organ dysfunction.197 However, it was recently reported
that, in meningococcal septic shock patients compared to non-shock
affected subjects, the EVs possessed increased pro-coagulant activ-
ity.214 Overall, patients with sepsis could significantly benefit from
early detection of biomarkers predicting the onset of DIC, leading
to early and more efficient management and therapy. CD31+ EVs
and CD105+ EVs are candidates for these biomarkers that warrant
further validation.195,215
Conclusions
Despite many studies, sepsis remains a complex clinical condition
whose pathophysiology is incompletely understood. Non-coding
RNAs present an opportunity for early diagnosis as well as an ability
to interact with key points of the biological mechanisms, suggesting
that measurement of the expression of miRNAs is a promising
approach for intensive care patients. The well-investigated markers
are miR-4772-5p, miR-4722-5p-iso, miR-4772-3p, miR-576-5p,
miR-146a, miR-133a, and miR-150, which all have higher concentra-
tions in patients with sepsis. Alternatively, miR-122, miR-181b, and
miR-223 have lower concentrations in sepsis patients. Furthermore,
in critically ill polytrauma patients, these biomarkers can be detected
in various body fluids, including blood, plasma, and serum, wideningthe options for the epigenetic detection of sepsis. Until now, epige-
netic interactions have not been widely documented in sepsis, and
more investigations are required to determine the role of the expres-
sion of miRNAs.
Exosomes may be able to prevent the occurrence of excess inflamma-
tion, thereby reducing mortality as well as lessening morbidity. Since
the majority of these investigations have been performed in experi-
mental models, further studies are required to translate the findings
into clinical applications.
Exosomes isolated from urine, cerebrospinal fluid, saliva, and plasma
can serve as prognostic and diagnostic markers for liver injury, kidney
disease, neurodegenerative diseases, and cancer. Clinical studies of
exosomes, including their use as drug-delivery systems, have shown
some promising results. It is accepted that any treatment that inter-
acts with basic biological processes carries a considerable risk of
causing undesirable side effects. Drug development and drug delivery
investigations based on exosomes, which are intended for future ther-
apeutic applications, must undergo a comprehensive and strict risk
and safety analysis before these agents can be tested in human studies.
The future perspective of miRNAs as an emerging therapeutic option
is not only due to the fact that miRNAs contain an entirely known
sequence that is often completely conserved among species, but
they are also relatively easily synthesized and can be manufactured
in bulk. Moreover, there still needs to be more knowledge about
which specific circulating miRNAs are deregulated in sepsis in order
to develop sensitive and specific screening biomarkers. Fortunately,
miRNA profiling data can be obtained from multiple pooled samples
as a promising way to identify potential miRNA biomarkers. More-
over, miRNA profiling combined with sensitive, accurate, and flexible
detection systems, such as small RNA sequencing, quantitative PCR
methods for miRNAs in circulating blood, and analysis of complex
datasets by powerful bioinformatics/biostatistical algorithms, will
work together to produce innovative miRNA-based diagnostic and
prognostic biomarkers.
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